JP2017066081A - 血中中性脂肪上昇抑制用組成物 - Google Patents
血中中性脂肪上昇抑制用組成物 Download PDFInfo
- Publication number
- JP2017066081A JP2017066081A JP2015193142A JP2015193142A JP2017066081A JP 2017066081 A JP2017066081 A JP 2017066081A JP 2015193142 A JP2015193142 A JP 2015193142A JP 2015193142 A JP2015193142 A JP 2015193142A JP 2017066081 A JP2017066081 A JP 2017066081A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- composition
- neutral fat
- acid
- suppressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 140
- 239000008280 blood Substances 0.000 title claims abstract description 140
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 29
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 30
- 229920002472 Starch Polymers 0.000 claims abstract description 14
- 239000008107 starch Substances 0.000 claims abstract description 14
- 235000019698 starch Nutrition 0.000 claims abstract description 14
- 230000001603 reducing effect Effects 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 9
- 150000002596 lactones Chemical class 0.000 claims abstract description 9
- 239000008101 lactose Substances 0.000 claims abstract description 9
- 239000007857 degradation product Substances 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 7
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 6
- 125000003172 aldehyde group Chemical group 0.000 claims abstract description 5
- 230000007935 neutral effect Effects 0.000 claims description 65
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims description 25
- JYTUSYBCFIZPBE-UHFFFAOYSA-N Maltobionic acid Natural products OC(=O)C(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O JYTUSYBCFIZPBE-UHFFFAOYSA-N 0.000 claims description 24
- 150000003626 triacylglycerols Chemical class 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 17
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 claims description 12
- 238000006276 transfer reaction Methods 0.000 claims description 9
- 239000007795 chemical reaction product Substances 0.000 claims description 8
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 6
- 229940099563 lactobionic acid Drugs 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims description 6
- FSICMNGKCHFHGP-QOKIMYEXSA-N D-maltobiono-1,5-lactone Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(=O)[C@H](O)[C@H]1O FSICMNGKCHFHGP-QOKIMYEXSA-N 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 4
- MUUBPEHTAPZMCA-NFXSTIHLSA-N (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoic acid Chemical compound OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O MUUBPEHTAPZMCA-NFXSTIHLSA-N 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 150000001879 copper Chemical class 0.000 claims description 3
- 150000002505 iron Chemical class 0.000 claims description 3
- 159000000003 magnesium salts Chemical class 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 150000003751 zinc Chemical class 0.000 claims description 3
- FSICMNGKCHFHGP-AMTLMPIISA-N lactobiono-1,5-lactone Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(=O)[C@H](O)[C@H]1O FSICMNGKCHFHGP-AMTLMPIISA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 208000032928 Dyslipidaemia Diseases 0.000 abstract description 7
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 5
- 206010008118 cerebral infarction Diseases 0.000 abstract description 5
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 5
- 208000010125 myocardial infarction Diseases 0.000 abstract description 5
- 235000014593 oils and fats Nutrition 0.000 abstract description 4
- 206010027476 Metastases Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000000376 reactant Substances 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 63
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 230000009471 action Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 16
- JYTUSYBCFIZPBE-ZNLUKOTNSA-N cellobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-ZNLUKOTNSA-N 0.000 description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 14
- 239000011575 calcium Substances 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000002960 lipid emulsion Substances 0.000 description 10
- 239000000306 component Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000002970 Calcium lactobionate Substances 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- 229940050954 calcium lactobionate Drugs 0.000 description 6
- 235000019307 calcium lactobionate Nutrition 0.000 description 6
- RHEMCSSAABKPLI-SQCCMBKESA-L calcium;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate Chemical compound [Ca+2].[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RHEMCSSAABKPLI-SQCCMBKESA-L 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000589236 Gluconobacter Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 241000186339 Thermoanaerobacter Species 0.000 description 1
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- -1 hypertension Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004045 soybean oil emulsion Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
に示すとおりの化合物である。コレステロールは血中ではリポタンパク質と複合体を形成し、リポタンパク質の種類によって、LDL(Low Density Lipoprotein)コレステロール(いわゆる、悪玉コレステロール)やHDL(High Density Lipoprotein)コレステロール(いわゆる、善玉コレステロール)などとよばれる。
により示される。
本発明の血中中性脂肪上昇抑制用組成物は、有効成分として、糖カルボン酸並びにその塩及びそのラクトンからなる群から選ばれる1種又はそれらの2種以上を少なくとも含有することを特徴とする。
マルトビオン酸カルシウム(サンエイ糖化株式会社製)、ラクトビオン酸カルシウム(サンエイ糖化株式会社製)及びマルトオリゴ糖酸化物(サンエイ糖化株式会社製)を用いた。なお、マルトオリゴ糖酸化物中(HPLC法;固形分換算)には、マルトビオン酸 67.2wt%に加えて、グルコン酸 0.7wt%、マルトトリオン酸 24.4wt%及びマルトテトラオン酸(重合度4)以上のマルトオリゴ糖酸化物 約7.7wt%を含む。また、マルトオリゴ糖酸化物の水分(常圧乾燥法)は32.9%であった。マルトビオン酸カルシウム及びラクトビオン酸カルシウムは純品相当のものを用いた。
純水を溶媒として、各被験物質が下記表1に記載の濃度になるように調製して、被験試料とした。
7週齢の雄性SD系ラット(日本クレア株式会社から入手)を、試験環境下で8日間馴化した。飼育環境として、照明時間は12時間とし、ケージは木材チップ(ソフトチップ;日本エスエルシー株式会社)を床じきとしたポリカーボネイト製平底ケージ(W260×D420×H180mm;日本クレア株式会社)を用いた。収容個体数は、1ケージあたり2〜3匹とした。
被験動物を、試験前日から14時間程度絶食させ、被験試料投与前(0分)の血中TG濃度及び体重がほぼ均一になるように、各群が7匹になるように群分けした(優先順位:血中TG濃度>体重)。体重測定には、電子天秤(DH−R1500N;新光電子株式会社)を用いた。
脂質エマルジョンの投与前(0)、投与1、2及び3時間後の血中TG濃度の測定結果の平均値及び標準偏差の推移を表2及び図1に示す。コントロール群と比較して、被験物質群では投与1時間後から血中TG濃度の低下傾向がみられた。特に、マルトビオン酸2000群、マルトビオン酸Ca2000群及びラクトビオン酸Ca2000群では、投与2時間後において、顕著な血中TG濃度の低下がみられた。また、投与3時間後以降は、被験物質の間で血中TG濃度に明らかな差異はみられなくなった。これらの結果から、マルトオリゴ糖酸化物、マルトビオン酸カルシウム及びラクトビオン酸カルシウムは脂質エマルジョン投与に伴う血中TG濃度の急激な上昇を抑制する作用を有し、投与1時間後という早期において脂質エマルジョン投与の影響を緩和して血中TG濃度を低下する作用を有することがわかった。
Claims (8)
- 重合度2以上の澱粉分解物、転移反応物又は乳糖の還元末端側のアルデヒド基が酸化された糖カルボン酸並びにその塩及びそのラクトンからなる群から選ばれる1種又は2種以上を含有する、血中中性脂肪上昇抑制用組成物。
- 前記糖カルボン酸が、マルトビオン酸、イソマルトビオン酸、マルトトリオン酸、イソマルトトリオン酸、マルトテトラオン酸、マルトヘキサオン酸及びラクトビオン酸からなる群から選ばれる1種又は2種以上を含む、請求項1に記載の血中中性脂肪上昇抑制用組成物。
- 前記糖カルボン酸が、マルトオリゴ糖酸化物、分岐オリゴ糖酸化物、水飴酸化物、粉飴酸化物又はデキストリン酸化物の形態で含まれる、請求項1又は2に記載の血中中性脂肪上昇抑制用組成物。
- 前記塩が、カルシウム塩、マグネシウム塩、ナトリウム塩、鉄塩、カリウム塩、亜鉛塩及び銅塩からなる群から選ばれる1種又は2種以上を含む、請求項1〜3のいずれか1項に記載の血中中性脂肪上昇抑制用組成物。
- 前記ラクトンが、マルトビオノラクトン、イソマルトビオノラクトン、マルトトリオノラクトン、イソマルトトリオノラクトン、マルトテトラオノラクトン、マルトヘキサオノラクトン及びラクトビオノラクトンからなる群から選ばれる1種又は2種以上を含む、請求項1〜4のいずれか1項に記載の血中中性脂肪上昇抑制用組成物。
- 前記血中中性脂肪上昇抑制用組成物は、外因性の中性脂肪による血中中性脂肪の上昇を抑制するために使用される、請求項1〜5のいずれか1項に記載の血中中性脂肪上昇抑制用組成物。
- 前記血中中性脂肪上昇抑制用組成物は、油脂含有物を摂取する前に投与される、請求項1〜6のいずれか1項に記載の血中中性脂肪上昇抑制用組成物。
- 前記血中中性脂肪上昇抑制用組成物は、食事摂取に伴う一時的な血中中性脂肪上昇抑制用組成物である、請求項1〜7のいずれか1項に記載の血中中性脂肪上昇抑制用組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015193142A JP6547122B2 (ja) | 2015-09-30 | 2015-09-30 | 血中中性脂肪上昇抑制用組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015193142A JP6547122B2 (ja) | 2015-09-30 | 2015-09-30 | 血中中性脂肪上昇抑制用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017066081A true JP2017066081A (ja) | 2017-04-06 |
JP6547122B2 JP6547122B2 (ja) | 2019-07-24 |
Family
ID=58494146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015193142A Active JP6547122B2 (ja) | 2015-09-30 | 2015-09-30 | 血中中性脂肪上昇抑制用組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6547122B2 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08291192A (ja) * | 1995-04-25 | 1996-11-05 | Nippon Shokuhin Kako Co Ltd | ラクトン化オリゴ糖、その製造方法及びα−アミラーゼ阻害剤 |
JP2010035513A (ja) * | 2008-08-07 | 2010-02-18 | San-Ei Sucrochemical Co Ltd | べーカリー製品用品質改良剤 |
JP2013067663A (ja) * | 2013-01-21 | 2013-04-18 | San-Ei Sucrochemical Co Ltd | 脂質代謝改善剤 |
-
2015
- 2015-09-30 JP JP2015193142A patent/JP6547122B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08291192A (ja) * | 1995-04-25 | 1996-11-05 | Nippon Shokuhin Kako Co Ltd | ラクトン化オリゴ糖、その製造方法及びα−アミラーゼ阻害剤 |
JP2010035513A (ja) * | 2008-08-07 | 2010-02-18 | San-Ei Sucrochemical Co Ltd | べーカリー製品用品質改良剤 |
JP2013067663A (ja) * | 2013-01-21 | 2013-04-18 | San-Ei Sucrochemical Co Ltd | 脂質代謝改善剤 |
Also Published As
Publication number | Publication date |
---|---|
JP6547122B2 (ja) | 2019-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4553604B2 (ja) | 一般食品、保健機能食品または健康補助食品の機能増強組成物及びその方法 | |
JP2009173634A (ja) | ポリ−γ−グルタミン酸を含有する脂質吸収阻害剤 | |
AU2004210244C1 (en) | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides | |
WO2007122801A1 (ja) | Gip分泌抑制剤 | |
JP2002154977A (ja) | 飲食用組成物 | |
US10376485B2 (en) | Metabolic syndrome ameliorating agent | |
WO2007139024A1 (ja) | 脂質代謝改善用組成物 | |
JP2008255040A (ja) | アディポネクチン産生促進剤 | |
JP2011037842A (ja) | 血中gip濃度上昇抑制剤 | |
JP6026723B2 (ja) | Gip上昇抑制剤 | |
WO2005039559A1 (ja) | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 | |
EP3657963A1 (en) | Composition for use in the prevention and treatment of pathologies of the cardiovascular apparatus | |
JP2009269865A (ja) | 経口投与剤 | |
JP6547122B2 (ja) | 血中中性脂肪上昇抑制用組成物 | |
US20110003896A1 (en) | Dimeric double metal salts of (-)-hydroxycitric acid, methods of making and uses of same | |
JP2006328010A (ja) | フロロタンニン含有脂質代謝改善物質 | |
JP2009126837A (ja) | 食後gip及び/又は食後インスリン分泌抑制剤 | |
JP2007246443A (ja) | アディポネクチン分泌促進剤、インスリン抵抗性改善剤及び抗動脈硬化剤 | |
JP2016222562A (ja) | 血糖値上昇抑制組成物 | |
JP2011184311A (ja) | 新規二次胆汁酸低減剤 | |
JP5759663B2 (ja) | 皮膚バリア機能改善剤等 | |
JP6566356B2 (ja) | 血中中性脂肪上昇抑制組成物 | |
WO2023157948A1 (ja) | 経口用組成物 | |
JP5454873B2 (ja) | リパーゼ阻害活性を有する乳酸菌 | |
JP2009280501A (ja) | 内臓脂肪蓄積抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180604 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190423 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190524 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6547122 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |